Breaking Finance News

Vetr Inc. reported on Juno Therapeutics Inc (NASDAQ:JUNO), hiking its price target to $28.85 earlier today

Stating a potential downside of -0.01%, Vetr Inc. increased the stock price target of Juno Therapeutics Inc (NASDAQ:JUNO) to $28.85

Just yesterday Juno Therapeutics Inc (NASDAQ:JUNO) traded 1.86% higher at $29.11. JUNO’s 50-day average is $29.07 and its two hundred day average is $24.60. With the last stock price close up 15.83% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same period. Volume of trade was down over the average, with 722,929 shares of JUNO changing hands under the typical 1,846,710

Performance Chart

Juno Therapeutics Inc (NASDAQ:JUNO)

With a market capitalization of $0, Juno Therapeutics Inc has 52 week low of $17.52 and a 52 week high of $35.04 .

In addition to Vetr Inc. reporting its target price, a total of 11 firms have issued a report on the company. The average stock price target is $55.73 with 0 brokers rating the company a strong buy, zero equity analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and lastly zero analysts rating the company a sell.

More About Juno Therapeutics Inc (NASDAQ:JUNO)

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.